Asia
A look at a few biotechs which should outperform the market in 2018.
The incubator will be located at Merck Serono’s current facilities in Yavne, a town in central Israel.
The company will use the capital to support a China Phase III trial of APL-1202, a repurposed oral inhibitor of MetAP2.
After the transaction, it will be NovaBay’s largest shareholder with 6.6 million shares, 37% of the total.
The agency inspected the plant from May 15 to May 24, 2017, and observed that staffers at the plant were basically gaming the quality control system.
Nanjing Legend Biotech received a very large $350M upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate.
LP Pharma raised $30M in a B round led by state-owned SDIC Fund Management.
Walgreens Boots Alliance will reduce its ownership in its China drug distribution JV with Guangzhou Pharmaceutical Co. Ltd.
Taris is developing implanted, continuous delivery devices combined with known cancer drugs for bladder disease treatment.
The biosimilar company, which has a $419M market capitalization, operates in Taiwan and Wuhan, China.
PRESS RELEASES